These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1304 related articles for article (PubMed ID: 15380544)

  • 1. Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft.
    Donckier V; Troisi R; Toungouz M; Colle I; Van Vlierberghe H; Jacquy C; Martiat P; Stordeur P; Zhou L; Boon N; Lambermont M; Schandené L; Van Laethem JL; Noens L; Gelin M; de Hemptinne B; Goldman M
    Transpl Immunol; 2004; 13(2):139-46. PubMed ID: 15380544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early immunosuppression withdrawal after living donor liver transplantation and donor stem cell infusion.
    Donckier V; Troisi R; Le Moine A; Toungouz M; Ricciardi S; Colle I; Van Vlierberghe H; Craciun L; Libin M; Praet M; Noens L; Stordeur P; Andrien M; Lambermont M; Gelin M; Bourgeois N; Adler M; de Hemptinne B; Goldman M
    Liver Transpl; 2006 Oct; 12(10):1523-8. PubMed ID: 17004249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver transplantation followed by adjuvant nonmyeloablative hemopoietic stem cell transplantation for advanced primary liver cancer in humans.
    Söderdahl G; Barkholt L; Hentschke P; Mattsson J; Uzunel M; Ericzon BG; Ringdén O
    Transplantation; 2003 Apr; 75(7):1061-6. PubMed ID: 12698103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
    Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
    Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
    Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.
    Carella AM; Lerma E; Dejana A; Corsetti MT; Celesti L; Bruni R; Benvenuto F; Figari O; Parodi C; Carlier P; Florio G; Lercari G; Valbonesi M; Casarino L; De Stefano F; Geniram A; Venturino M; Tedeschi L; Palmieri G; Piaggio G; Podestà M; Frassoni F; Van Lint MT; Marmont AM; Bacigalupo A
    Haematologica; 1998 Oct; 83(10):904-9. PubMed ID: 9830799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-T-lymphocyte globulin based non-myeloablative stem cell transplantation followed by HLA-identical donor lymphocyte infusion for hematologic malignancies.
    Mao P; Wang S; Wang H; Li Q; Xu Y; Mo W; Ying Y; Zhu Z
    Chin Med J (Engl); 2003 Jan; 116(1):70-3. PubMed ID: 12667392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Application of FBC conditioning regimen in HLA haplotype peripheral blood stem cell transplantation].
    Wu B; Guo K; Song Z; Yan D; Yang Y; Xiao L
    Zhonghua Xue Ye Xue Za Zhi; 2002 Apr; 23(4):194-7. PubMed ID: 12133456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Non-myeloablative stem cell transplant].
    Shoji N; Mineishi S
    Gan To Kagaku Ryoho; 2000 Jun; 27(6):795-800. PubMed ID: 10897204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrochimerism of donor type CD56+ CD3+ T cells in donor specific transfusion via portal vein following living related donor liver transplantation.
    Sato Y; Ichida T; Watanabe H; Yamamoto S; Abo T; Hatakeyama K
    Hepatogastroenterology; 2003; 50(54):2161-5. PubMed ID: 14696487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver transplant for hepatocellular carcinoma: experience in a Saudi population.
    Allam N; Khalaf H; Fagih M; Al-Sebayel M
    Exp Clin Transplant; 2008 Mar; 6(1):14-24. PubMed ID: 18405240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graft survival and immune regulation of pancreas allograft recipients induced with thymoglobulin, sirolimus, and cyclosporine.
    Knight RJ; Kerman RH; Podder H; Katz SM; Van Buren CT; Kahan BD
    Transplant Proc; 2005 Mar; 37(2):1280-2. PubMed ID: 15848695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
    Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
    Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graft rejection and hyperacute graft-versus-host disease in stem cell transplantation from non-inherited maternal-antigen-complementary HLA-mismatched siblings.
    Okumura H; Yamaguchi M; Kotani T; Sugimori N; Sugimori C; Ozaki J; Kondo Y; Yamazaki H; Chuhjo T; Takami A; Ueda M; Ohtake S; Nakao S
    Eur J Haematol; 2007 Feb; 78(2):157-60. PubMed ID: 17313562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
    Muñoz A; Olivé T; Martinez A; Bureo E; Maldonado MS; Diaz de Heredia C; Sastre A; Gonzalez-Vicent M;
    Pediatr Hematol Oncol; 2007 Sep; 24(6):393-402. PubMed ID: 17710656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality.
    Hartwig UF; Winkelmann N; Wehler T; Kreiter S; Schneider PM; Meyer RG; Ullmann AJ; Huber C; Kolbe K; Herr W
    Ann Hematol; 2005 May; 84(5):331-8. PubMed ID: 15726363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerance induction in clinical transplantation.
    Fehr T; Sykes M
    Transpl Immunol; 2004; 13(2):117-30. PubMed ID: 15380542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.